Logo image
Dr. med. Daniel Sasca working place, University Hospital Johannes Gutenberg Mainz
Dr. med. Daniel Sasca
Excellent
AiroScore
9.70

Dr. med. Daniel Sasca

internal medicine, hematology, oncology, and drug-based tumor therapy
internal medicine, hematology, oncology, and drug-based tumor therapy
User ScoreExperienceRatingPrice RangePublicationsOnline Consultations
90%16 years9.7/10$$$27No

Overview

Country, City
Germany, Mainz
Health facility
University Hospital Johannes Gutenberg Mainz
Medical unit
Department of hematology and medical oncology

About the doctor

Dr. med. Daniel Sasca is an experienced doctor specializing in internal medicine, hematology, oncology, and drug-based tumor therapy. With 15 years of experience, Dr. Sasca has established himself as a prominent figure in his field. He has an impressive CV, including studying human medicine, obtaining a license for medical practice, and defending his dissertation. He has also received additional hematology, oncology, and drug-based tumor therapy qualifications. Dr. Sasca has worked at the prestigious University Hospital Johannes Gutenberg Mainz and has made significant contributions. He started as a Senior Physician in the Department of hematology and medical oncology and later became the Head of the Department in 2018. He has published 27 scientific publications during his tenure, focusing on leukemogenesis, drug resistance in acute myeloid leukemia, and epigenetic modulation in myeloid neoplasms. His publications highlight his dedication and expertise in his field. Dr. Sasca's extensive experience, specialization, and contributions to scientific research make him a highly respected and skilled doctor. He is committed to providing the best possible care to his patients and staying at the forefront of advancements in his field. Patients in Germany, especially in Mainz, can trust Dr. Sasca for his expertise and knowledge in internal medicine, hematology, oncology, and drug-based tumor therapy.

Skills & Expertise

leukemia
oncology
hematology
myeloid leukemia
tumor
drug resistance
tumor therapy
gene expression
internal medicine
drugbased tumor therapy
npm1 mutation
mutational synergy
chromatin regulation
myeloid neoplasms
stem cell
matrixassociated protein safb
venetoclax
cd56
ziftomenib
mutation
neoplasms
ncam1
expression flt3itd
deregulation interferon signal
disturbed erythropoiesis
p53 activation
lymphoid progenitors
flt3 mutations
myelogenous leukemias
mutant variants
kras mutant
monocytic cells
metabolic dependency
znf217 mutations
hairycell leukemia
hoxa9 forms
urologic oncology
cell lymphoma
myeloid malignancies
hairycell
trem1
glutaminolysis
lymphoid
sirt1
neutrophils
erythropoiesis
malignancies
interferon
lymphoma
chemotherapy

Resume

CV (Curriculum Vitae)

Education
  • Studied human medicine
  • Obtaining a license for medical practice
  • Defense of the dissertation
  • Obtaining specialization in internal medicine
  • Habilitation and a teaching license
  • Received additional qualifications in the field of hematology, oncology, and drug-based tumor therapy
  • 2015-2017 Postdoctoral Fellow at the University of Cambridge, Stem Cell Institute
Experience
  • 2008-2017 Senior Physician of the Department of hematology and medical oncology at the University Hospital Johannes Gutenberg Mainz
  • 2018 Head of the Department of hematology and medical oncology at the University Hospital Johannes Gutenberg Mainz

Languages

English flag
English
German flag
German

Publications

Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma.

30 August, 2023

Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax.

27 April, 2023

HOXA9 forms a repressive complex with nuclear matrix-associated protein SAFB to maintain acute myeloid leukemia.

6 April, 2023

Location

Langenbeckstraße, 1, 55131 Mainz, Germany

FAQ

What is the specialization of Dr. med. Daniel Sasca?

The primary specialization of the doctor is internal medicine, hematology, oncology, and drug-based tumor therapy.

What is the experience of the specialist?

Dr. med. Daniel Sasca has been practicing for more than 16 years.

What is the rating of the doctor?

Dr. med. Daniel Sasca is rated as 9.70 by AiroMedical.

What topics does Dr. med. Daniel Sasca expert at?

The doctor has excellent knowledge in leukemia, oncology, hematology, myeloid leukemia, tumor.

Is the specialist involved in the research?

Does the specialist offer online consultations?

No, Dr. med. Daniel Sasca doesn’t perform virtual appointments.

Dr. med. Daniel Sasca
Dr. med. Daniel Sasca

Get individual treatment plan and cost estimate. Non-binding 100% free assessment.

© Dr. med. Daniel Sasca

Similar Doctors

Excellent
AiroScore
9.70
University Hospital Johannes Gutenberg Mainz
gynecology, obstetrics, gynecological oncology, and breast tumors
Excellent
AiroScore
9.70
University Hospital Johannes Gutenberg Mainz
internal medicine, nephrology, hypertension, and rheumatology
Excellent
AiroScore
9.70
University Hospital Johannes Gutenberg Mainz
internal medicine, pulmonology, and allergology
Excellent
AiroScore
9.70
University Hospital Johannes Gutenberg Mainz
internal medicine, angiology, cardiology, and hemostaseology
Excellent
AiroScore
9.70
Excellent
AiroScore
9.70
Excellent
AiroScore
9.70
University Hospital Johannes Gutenberg Mainz
internal medicine, geriatrics, intensive care, and physical therapy
Excellent
AiroScore
9.70
University Hospital Johannes Gutenberg Mainz
internal medicine, endocrinology, diabetology, and nutritional medicine